LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)

UCB

Status and phase: Completed; Phase 4

Conditions: Rhinitis, Allergic, Perennial

Treatments: Drug: Levocetirizine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00160589

A00401

LEADER

EudraCT2004-002823-42

Details and patient eligibility

About

Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 2-year history of Allergic Rhinitis that became symptomatic during the annual grass pollen season.
• A skin test for grass pollens positive:
• Have rhinitis symptoms of such severity that the mean T4SS over the baseline period must be 6.

Exclusion criteria

• Have an associated asthma requiring corticosteroid treatment,
• Have an atopic dermatitis or an urticaria requiring an antihistamine treatment or the administration of oral or topical corticosteroids,